Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center

Read as PDF

Lund, Sweden, 22th of June 2017 - Xintela AB (publ) announces that the company is a partner in a project, financed by Vinnova and Vetenskapsrådet, to establish an international research center for effective production and development of Advanced Therapy Medicinal Products in cell and gene therapy. The project has been granted 48 MSEK in financing and will have a duration of six years.

As one of the founders responsible for the establishment of the international research center, named Centre for Advanced Medical Products (CAMP), Xintela will interact with, among others, AstraZeneca, GE Healthcare, Pfizer, all Swedish universities as well as several health care regions and research institutions. The goal is to gain international recognition.

“It is gratifying that the Swedish government, Vinnova and Vetenskapsrådet acknowledge the huge potential of cell and gene therapy and the strong position that Sweden has in this research field. Xintela is one of the companies in Sweden with large development potential in cell therapy, which makes us a natural partner for this project. Vi expect this initiative to support our own development projects as well as the research field in general”, says Xintelas CEO Evy Lundgren-Åkerlund.

Initially, Xintela will contribute as an advisor for the development of the center. Over time the company expects to benefit from the research and development and the knowledge that the center will facilitate, as well as contacts with other internationally leading companies and researchers.

The initiative to establish a research center is included in an eight-year research program for biologics totaling 320 million SEK, which is a part of the Swedish government’s strategic cooperation program in life science. The aim is for Sweden to be a leader in the development of this field.

About CAMP - Centre for Advanced Medical Products
CAMP aims to establish itself as an internationally recognized center focusing on industry growth and small and medium size enterprises, clinical practice, research and education, advanced production technology and a prominent innovation and business environment. In the longer term, the center can help attract investment from the global life science industry, including pharmaceuticals, biotech, medical technology and service industries.

For more information on the initiative, read the press release from Vinnova (in Swedish) that was published on the 19th of June: http://www.mynewsdesk.com/se/vinnova/pressreleases/stor-satsning-paa-forskningscentrum-ska-goera-sverige-ledande-inom-biologiska-laekemedel-2024172

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village 223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK®. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces.  The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique way, quality assure stem cells for the repair of damaged cartilage. The XINMARK®-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 22th of June 2017, at 10.00 CET.